Email Alert | RSS

Journal of Peking University(Health Sciences) ›› 2019, Vol. 51 ›› Issue (3): 409-413. doi: 10.19723/j.issn.1671-167X.2019.03.006

Previous Articles     Next Articles

Haploidentical allogenetic hematopoietic stem cell transplantation for X-linked adrenoleukodystrophy

Yao Chen1,2,Xiao-hui ZHANG1,2,Lan-ping XU1,2,Kai-yan LIU1,2,Jiong QIN3,Yan-ling YANG4,Xiao-jun HUANG1,2△()   

  1. 1. Peking University People’s Hospital, Peking University Institute of Hematology,Beijing 100044, China
    2. Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Diseases, Beijing 100044, China
    3. Department of Pediatrics, Peking University People’s Hospital, Beijing 100044, China
    4. Department of Pediatrics, Peking University First Hospital, Beijing 100034, China
  • Received:2019-03-11 Online:2019-06-18 Published:2019-06-26
  • Supported by:
    Supported by National Natural Science Foundation(81621001)

RICH HTML

 38   

PDF (PC)

424

Abstract: Objective: X-linked adrenoleukodystrophy (ALD) is a severe inherited disorder leading to rapid neurological deterioration and premature death. Allogeneic hematopoietic stem cell transplantation (HSCT) is still the only treatment that halts the neurologic symptoms in ALD. However, many patients lack suitable human leukocyte antigen (HLA) matched related donors and must rely on alternative donors for a source of stem cells. The purpose of this study was to explore the outcomes of haploidentical allogeneic stem cell transplantation for ALD patients.Methods: Between December 2014 and December 2018, eight children with ALD lacking HLA matched related or unrelated donors were treated with haploidentical allogeneic hematopoietic stem cell transplantation. The patients received conditioning regimen with busulfan 9.6 mg/kg, cyclophosphamide 200 mg/kg and fludarabine 90 mg/m 2. Graft-versus-host disease (GVHD) prophylaxis consisted of anti-human thymocyte globulin, cyclosporine A, mycophenolate mofetil and short course of methotrexate. Results: All the 8 children received allogeneic stem cell transplants from their fathers. The median age of the recipients was 8 (range: 5-12) years. The median age of the donors was 36 (range: 32-40) years. All the recipients received granulocyte colony-stimulating factor (G-CSF) mobilized bone marrow and peripheral blood-derived stem cells. The median number of total mononuclear cells dose and CD34 + dose was 10.89 (range: 9.40-12.16)×10 8/kg and 7.06 (range: 0.74-7.80)×10 6/kg, respectively. Neutrophil engraftment occurred a median of 11 days (range:8-13 days) after transplantation. Platelet engraftment occurred a median of 10 days (range:8-12 days) after transplantation. All the patients achieved complete donor chimerism at the time of engraftment. Four patients had grades Ⅱ-Ⅳ acute GVHD and 1 had chronic graft-versus-host disease. No severe chronic GVHD occurred. Among all the children, 2 had cytomegalovirus (CMV) DNAemia and 2 Epstein-Barr virus (EBV) DNAemia. Overall, seven of them survived and had no major complications related to transplantation. One died of cerebral hernia after epilepsy 125 days after transplantation. Conclusion: The preliminary observation demonstrates that haploidentical allogeneic stem cell transplantation with this novel regimen could successfully achieve full donor chimerism in ALD patients. According to our experience, haploidentical allogeneic hematopoietic stem cell transplantation is safe and feasible in the treatment of X-linked adrenoleukodystrophy.

Key words: Haploidentical, Allogeneic hematopoietic stem cell transplantation, X-linked adrenoleukodystrophy, Graft-versus-host disease

CLC Number: 

  • R551.3
[1] Igarashi M, Schaumburg HH, Powers J , et al. Fatty acid abnormality inadrenoleukodystrophy[J]. J Neurochem, 1976,26(4):851-860.
doi: 10.1111/jnc.1976.26.issue-4
[2] Mahmood A, Dubey P, Moser HW , et al. X-linked adrenoleukodystrophy: therapeutic approaches to distinct phenotypes[J]. Pediatr Transplant, 2005,9(Suppl 7):55-62.
doi: 10.1111/ptr.2005.9.issue-s7
[3] Aubourg P, Blanche S, Jambaque I , et al. Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation[J]. N Engl J Med, 1990,322(26):1860-1866.
doi: 10.1056/NEJM199006283222607
[4] Mahmood A, Raymond GV, Dubey P , et al. Survival analysis of haematopoietic cell transplantation for childhood cerebral X-linked adrenoleukodystrophy: a comparison study[J]. Lancet Neurol, 2007,6(8):687-692.
doi: 10.1016/S1474-4422(07)70177-1
[5] Wang Y, Chang YJ, Xu LP , et al. Who is the best donor for a related HLA haplotype-mismatched transplant?[J]. Blood, 2014,124(6):843-850.
doi: 10.1182/blood-2014-03-563130
[6] Xu LP, Xu ZL, Wang FR , et al. Unmanipulated haploidentical transplantation conditioning with busulfan, cyclophosphamide and anti-thymoglobulin for adult severe aplastic anaemia[J]. Bone Marrow Transplant, 2018,53(2):188-192
doi: 10.1038/bmt.2017.237
[7] Bashey A, Zhang X, Sizemore CA , et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched rela-ted and unrelated donor transplantation[J]. J Clin Oncol, 2013,31(10):1310-1316.
doi: 10.1200/JCO.2012.44.3523
[8] Kühl JS, Kupper J, Baqué H , et al. Potential risks to stable long-term outcome of allogeneic hematopoietic stem cell transplantation for children with cerebral X-linked adrenoleukodystrophy[J]. JAMA Netw Open, 2018,1(3):e180769.
doi: 10.1001/jamanetworkopen.2018.0769
[9] Chen Y, Xu LP, Zhang XH , et al. Busulfan, fludarabine, and cyclophosphamide (BFC) conditioning allowed stable engraftment after haplo-identical allogeneic stem cell transplantation in children with adrenoleukodystrophy and mucopolysaccharidosis[J]. Bone Marrow Transplant, 2018,53(6):770-773.
doi: 10.1038/s41409-018-0175-8
[10] Przepiorka D, Weisdorf D, Martin P , et al. 1994 consensus conference on acute GVHD grading[J]. Bone Marrow Transplant, 1995,15(6):825-828.
[11] Martin PJ, Lee SJ, Przepiorka D , et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: Ⅵ. The 2014 Clinical Trial Design Working Group Report[J]. Biol Blood Marrow Transplant, 2015,21(8):1343-1359.
doi: 10.1016/j.bbmt.2015.05.004
[12] 赵晓甦, 刘代红, 许兰平 , 等. 异基因造血干细胞移植后巨细胞病毒肺炎临床特点分析[J]. 北京大学学报(医学版), 2009,41(5):548-553.
[13] 许兰平, 刘代红, 刘开彦 , 等. 利妥昔单抗治疗异基因造血干细胞移植后EB病毒病的疗效和安全性[J]. 中华内科杂志, 2012,51(12):966-970.
doi: 10.3760/cma.j.issn.0578-1426.2012.12.010
[14] Peters C, Shapiro EG, Anderson J , et al. Hurler syndrome: Ⅱ. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease Collaborative Study Group[J]. Blood, 1998,91(7):2601-2608.
[15] Fernandes JF, Bonfim C, Kerbauy FR , et al. Haploidentical bone marrow transplantation with post transplant cyclophosphamide for patients with X-linked adrenoleukodystrophy: a suitable choice in an urgent situation[J]. Bone Marrow Transplant, 2018,53(4):392-399.
doi: 10.1038/s41409-017-0015-2
[16] Souillet G, Guffon N, Maire I , et al. Outcome of 27 patients with Hurler’s syndrome transplanted from either related or unrelated haematopoietic stem cell sources[J]. Bone Marrow Transplant, 2003,31(12):1105-1117.
doi: 10.1038/sj.bmt.1704105
[17] Chun HG, Leyland-Jones B, Cheson BD . Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies[J]. J Clin Oncol, 1991,9(1):175-188.
doi: 10.1200/JCO.1991.9.1.175
[18] Keating MJ , O’Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receivingfludarabine regimens as initial therapy[J]. Blood, 1998,92(4):1165-1171.
No related articles found!
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] Author. English Title Test[J]. Journal of Peking University(Health Sciences), 2010, 42(1): 1 -10 .
[2] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 188 -191 .
[3] . [J]. Journal of Peking University(Health Sciences), 2009, 41(4): 459 -462 .
[4] . [J]. Journal of Peking University(Health Sciences), 2010, 42(1): 82 -84 .
[5] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 319 -322 .
[6] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 333 -336 .
[7] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 337 -340 .
[8] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 225 -328 .
[9] . [J]. Journal of Peking University(Health Sciences), 2007, 39(4): 346 -350 .
[10] . [J]. Journal of Peking University(Health Sciences), 2007, 39(4): 351 -354 .
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd